Market Overview

FDA's Orange Book Doesn't Include Amarin's Vascepa NCE Status in November Report - Bloomberg

Related AMRN
UPDATE: What Amarin Would Need To Disclose To Ensure Non-Misleading Speech
First Amendment Decision a Win for Amarin and Physician Plaintiffs

View Orange Book.

Posted-In: News FDA


Related Articles (AMRN)

Get Benzinga's Newsletters